Comparison of efficacy of oralTranexamicAcid with4% topical hydroquinone in the treatment of melasma.

Comparison of Oral Transxamic Acid Effect with 4% Local Hydroquinone in the Treatment of Melasma

Patients are placed under a wood lamp examination and the type of melasma (dermal, epithelial, mixed, unspecified) is determined. It is explained to the patient about the manner in which the work is carried out and they are willing to obtain consent to enter the study. patients placed randomized in one of the groups A, which included administration of the topical hydroquinone 4% of the company Bahuzan, making Iran (cream Hydroquinone 4%) that is applied locally in the morning and night, or Group B containing the transaxamic acid capsule 250 mg of Amin Pharmaceutical Company, Iran (Trancid capsule 250 milligram) every 12 hours. Before the onset of each patient, the intensity of melasma was measured by the formula of the Melasma area and severity index (MASI) score and recorded separately for each patient. Each patient is treated for 3 months in each group for a period of 3 months and is followed up during the period and advised to use sunscreen (without anti-pigment content). Within 1 month and 3 months after starting treatment, each patient is reassessed and calculated for the MASI score. The sample size will be 31 in each group.

The study was performed on patients with melasma referred to Dermatology Clinic of Ahvaz Imam Khomeini Hospital. Imam Khomeini Hospital, Ahvaz Hospital. Dermatology clinic Blinding process ; As a record of the score of the MASI by a single person( the person with no knowledge from the patient group that studied) during the study.

Inclusion criteria : Patients with melasma aged 18 to 60 years. exclusion criteria: Patients with a history of coagulopathy, History of Thrombotic Problems Evidence for a thrombotic event, Using coagulant drugs, or antiplatelets, such as aspirin or clopidogrel tablets, Pregnancy Lactation Concomitant use of contraceptives, The history of vitiligo or other pigmentation disorders, Trancexamic Acid Sensitivity History kidney disease, History of treatment for clarifying melasma during 3 months before the start of the study.

Patients with melasma treated with Oral Transxamic Acid. Patients with melasma treated with topical hydroquinone 4%.

MASI SCORE. Sex Skin Phototype. Length of illness. family history. Type of melasma

According to the quadrilateral permutation blocks, patients are randomly divided into two groups. This treatment is administered to both groups for 3 months.

As a record of the MASI score by a single person during the study, it does not have any information about the patient group being studied. During the treatment period, if the patient complains or does not want to continue treatment, the study will be discontinued. During the sampling process, we will evaluate the MASI score as a baseline at the start of treatment, and at the 4th week - 12th and 3 months after the end of treatment, as well as at the end of the 3-month treatment, the patient's satisfaction with the treatment will be recorded in each group.

The total potential data can be shared after denationalization of people.

Start the access period 1 year after the results print.

Only available to scholars working in academia .

Only for statistical analysis or use in multi-center designs.

samin vala saminvala@gmail.com 009891633114629

Send request via academic email. we will Send the data file within one month from the time of request.